Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccine + Ipilimumab in Advanced Melanoma
NCT02275416Phase 2Completed
- Sponsor
- Ultimovacs ASA
- Start
- Feb 2015
- Primary completion
- Oct 2016
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in Malignant Melanoma (MM), sponsored by Ultimovacs ASA. Started Feb 2015; status: completed.
02
Drugs
UV1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02275416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275416.